Conversely, thrombotic risk factors included elevated titers of aPL in patients with primary PHT and CTEPH, 10% of the patients with primary PHT and 20% with CTEPH (91). This evidence concerns the gene FASLG and chronic thromboembolic pulmonary hypertension.